📰 Beigene News
Page 13 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
February 1, 2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology
January 19, 2023
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
January 19, 2023
MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
January 18, 2023
Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS included for the first time XGEVA successfully renewed BeiGene (NASDAQ: BGNE; HKEX:
January 17, 2023
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
January 4, 2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology companytoday announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conferenceon Monday, January
December 30, 2022
Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company
December 13, 2022
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual
December 9, 2022
09.12.2022 - BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) ... Seite 1
November 22, 2022
22.11.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation ... Seite 1